RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Stanley Hsia to Hypoglycemic Agents

This is a "connection" page, showing publications Stanley Hsia has written about Hypoglycemic Agents.
Connection Strength

1.463
  1. Machinani S, Bazargan-Hejazi S, Hsia SH. Psychological insulin resistance among low-income, U.S. racial minority patients with type 2 diabetes. Prim Care Diabetes. 2013 Apr; 7(1):51-5.
    View in: PubMed
    Score: 0.399
  2. Hsia SH, Navar MD, Duran P, Shaheen M, Davidson MB. Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus. Endocr Pract. 2011 Sep-Oct; 17(5):691-8.
    View in: PubMed
    Score: 0.365
  3. Frias JP, Bonora E, Nev?rez Ruiz L, Hsia SH, Jung H, Raha S, Cox DA, Bethel MA, Konig M. Efficacy and safety of dulaglutide 3.0?and 4.5?mg in patients aged?younger than?65 and?65?years or older: Post hoc analysis of the AWARD-11 trial. Diabetes Obes Metab. 2021 10; 23(10):2279-2288.
    View in: PubMed
    Score: 0.180
  4. Desouza CV, Holcomb RG, Rosenstock J, Frias JP, Hsia SH, Klein EJ, Zhou R, Kohzuma T, Fonseca VA. Results of a Study Comparing Glycated Albumin to Other Glycemic Indices. J Clin Endocrinol Metab. 2020 03 01; 105(3).
    View in: PubMed
    Score: 0.164
  5. Hsia SH, Duran P, Lee ML, Davidson MB. Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. J Diabetes. 2020 Jan; 12(1):91-94.
    View in: PubMed
    Score: 0.160
  6. Hsia SH. Insulin glargine compared to NPH among insulin-na?ve, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Res Clin Pract. 2011 Mar; 91(3):293-9.
    View in: PubMed
    Score: 0.087
  7. Hsia SH, Bazargan M, Davidson MB. Effect of Pancreas Tonic (an ayurvedic herbal supplement) in type 2 diabetes mellitus. Metabolism. 2004 Sep; 53(9):1166-73.
    View in: PubMed
    Score: 0.056
  8. Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, Kazda C, Mather KJ, Haupt A, Pratt E, Robins D. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023 08 05; 402(10400):472-483.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support